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Introduction
Muscle structure, mass, and composition are critical for motil-
ity, whole body metabolism, and viability. Skeletal muscle is 
composed of heterogeneous myofibers with distinct metabolic 
properties, rates of contraction, and susceptibility to fatigue 
M
ammalian target of rapamycin (mTOR) is a key 
regulator  of  cell  growth  that  associates  with 
raptor and rictor to form the mTOR complex 1 
(mTORC1) and mTORC2, respectively. Raptor is required 
for oxidative muscle integrity, whereas rictor is dispens-
able. In this study, we show that muscle-specific inactiva-
tion  of  mTOR  leads  to  severe  myopathy,  resulting  in 
premature death. mTOR-deficient muscles display meta-
bolic changes similar to those observed in muscles lacking 
raptor, including impaired oxidative metabolism, altered 
mitochondrial regulation, and glycogen accumulation 
associated with protein kinase B/Akt hyperactivation. 
In addition, mTOR-deficient muscles exhibit increased basal 
glucose uptake, whereas whole body glucose homeo-
stasis is essentially maintained. Importantly, loss of mTOR 
exacerbates the myopathic features in both slow oxida-
tive and fast glycolytic muscles. Moreover, mTOR but not 
raptor and rictor deficiency leads to reduced muscle 
dystrophin  content.  We  provide  evidence  that  mTOR 
controls dystrophin transcription in a cell-autonomous, 
rapamycin-resistant,  and  kinase-independent  manner. 
Collectively, our results demonstrate that mTOR acts mainly 
via mTORC1, whereas regulation of dystrophin is raptor 
and rictor independent.
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of  a YY1  (Yin Yang  1)–PGC1  transcriptional  complex 
(Cunningham et al., 2007). Consistent with this, muscle-specific 
inactivation of the mTORC1 component raptor in raptor mus-
cle knockout (RAmKO) mice leads to muscle atrophy, im-
paired  oxidative  capacity,  and  increased  glycogen  stores, 
resulting in dystrophic features that were most prominent in 
oxidative muscles (Bentzinger et al., 2008). In contrast, the 
muscle-specific  loss  of  the  mTORC2  component  rictor  in 
rictor muscle knockout (RImKO) mice has minimal impact on 
muscle  physiology  (Bentzinger  et  al.,  2008;  Kumar  et  al., 
2008),  and  raptor/rictor  muscle  double  knockout  (DmKO) 
show similar pathological changes as RAmKO mice. These 
studies suggested that mTOR functions in adult skeletal muscle 
require only mTORC1 (Bentzinger et al., 2008). However, there 
is evidence that some functions of mTOR, such as the activa-
tion of terminal oligopyrimidine mRNA translation, could be 
independent of mTORC1 and mTORC2 (Patursky-Polischuk 
et al., 2009).
The aim of this study was to determine the physiological 
functions of mTOR in differentiated mouse skeletal muscle. 
Because conventional mTOR knockout mice die during early 
embryogenesis (Gangloff et al., 2004; Murakami et al., 2004), 
we  generated  muscle-specific  mTOR  knockout  (mTOR
) 
mice. In this study, we show that these animals develop a   
severe myopathy, displaying features of muscular dystrophy 
(MD) and metabolic myopathy, leading to premature death 
between 22 and 38 wk of age. Although the metabolic altera-
tions are similar between mTOR
 and RAmKO/DmKO mice, 
mTOR deficiency more severely affects muscle contractile 
properties. In addition, mTOR
 muscles, in contrast to RAmKO 
and RImKO muscles, display reduced content of compo-
nents  of  the  dystrophin–glycoprotein  complex  (DGC).   
Finally, we demonstrate that mTOR controls dystrophin trans-
cription in a cell-autonomous, rapamycin-resistant, and kinase- 
independent manner.
(Bassel-Duby and Olson, 2006; Schiaffino et al., 2007) but ex-
hibits remarkable metabolic and morphological adaptive capa-
bilities in response to several physiological (e.g., exercise) and 
pathological (systemic diseases, myopathy, and aging) condi-
tions. These adaptive processes include hypertrophy, atrophy, 
regeneration, fiber type conversion, or mitochondrial biogenesis.
As a conserved Ser/Thr kinase, the mammalian target of 
rapamycin (mTOR) is a central regulator of cell growth by inte-
grating signals from nutrients, growth factors, energy status, and 
environmental  stress.  mTOR  resides  in  two  structurally  and 
functionally  distinct  signaling  complexes:  mTOR  complex  1 
(mTORC1)  and  mTORC2. The  raptor-containing  complex 
mTORC1 regulates a vast range of cellular activities, including 
transcription, translation, ribosome biogenesis, and autophagy 
(Wullschleger et al., 2006). A key cellular substrate for mTORC1 
is the ribosomal S6 kinase (S6K1), which is phosphorylated at its 
hydrophobic motif residue, Thr389. The rictor-containing com-
plex mTORC2 is proposed to regulate actin organization. More-
over,  mTORC2  is  one  of  the  kinases  able  to  phosphorylate 
PKB/Akt on Ser473 (Jacinto et al., 2004; Sarbassov et al., 2004; 
Bentzinger et al., 2008).
Under acute treatment, rapamycin is thought to selec-
tively  inhibit  mTORC1.  Conversely,  mTORC2  is  considered 
rapamycin  insensitive,  although  prolonged  treatment  disrupts 
mTORC2 assembly in certain cell lines (Sarbassov et al., 2006). In 
addition, the recent development of the ATP-competitive inhibitor 
Torin1, which suppresses both mTORC1 and mTORC2, allowed 
the  identification  of  rapamycin-resistant  mTORC1-dependent 
functions required for cap-dependent translation and suppression 
of autophagy (Thoreen et al., 2009).
Rapamycin-sensitive  mTORC1  functions  have  been 
shown to be required for muscle growth (Bodine et al., 2001; 
Rommel et al., 2001; Ohanna et al., 2005) as well as for the 
maintenance of mitochondrial oxidative function by directly 
regulating mitochondrial gene expression through the control 
Figure  1.  Muscle-specific  inactivation  of 
mTOR.  (A)  mTOR
flox  and  mTOR
  mice  were 
generated  as  described  in  Materials  and 
methods.  (B)  PCR  analysis  of  Cre-mediated 
recombination of the mTOR
flox allele (p2/p3) 
showing  that  the  deleted  mTOR  allele  (p1/
p3) was exclusively detected in skeletal mus-
cles of mTOR
 mice. C, control; , mTOR
.   
(C) Growth curves of mTOR
 and control female 
mice (n = 15 mice). (D) Morphology of 22-wk-
old female mTOR
 mice. (E) Survival curve of 
mTOR
  and  control  mice  (n  =  20).  **,  P  < 
0.01. Data indicate mean ± SD.861 mTOR deficiency leads to severe muscular dystrophy • Risson et al.
However, the reduction in mTOR-TA muscle mass was associ-
ated with a 24% decrease of the mean cross-sectional area (CSA), 
whereas mTOR
 soleus muscle displayed a 6% increase of the 
mean CSA (Fig. 2 A). In addition, mTOR
 muscles showed char-
acteristic dystrophic features that were exacerbated in oxidative 
muscles (Fig. 2 B). These included degeneration with phago-
cytosis and mononuclear cell infiltration (Fig. 2 B, green arrows), 
variation in fiber size with small atrophic fibers (Fig. 2 B, yellow 
arrows), interfiber connective tissue (Fig. 2 B, thin arrows), and a 
marked number of regenerated muscle fibers with centrally lo-
cated nuclei (Fig. 2 B, black arrows) that increased with age 
(Fig. 2 C). Ongoing muscle regeneration was further confirmed 
at the molecular level by the activation of the expression of peri-
natal muscle myosin heavy chain (MHC) MyH8, IGF-II, and 
myogenin (Fig. 2 D). Dystrophic hallmarks were prominent in 
the diaphragm, which additionally showed fibrosis (Fig. 2 B, as-
terisk) and fatty infiltration (Fig. 2 B, red arrows), suggesting that 
respiratory failure might be the cause of premature death.
To examine a potential relationship between the promi-
nent dystrophic features in oxidative muscles and fiber types, 
we analyzed the composition of MHC isoforms in whole mus-
cles from 6-wk-old mice. In soleus the shift was from MHC-2X 
toward MHC-1 (Fig. 2 E and Fig. S1), in TA from MHC-2B to-
ward MHC-2X and -2A (Fig. 2 F), and in PLA from MHC-2B 
toward MHC-2X and MHC-1 (Fig. 2 G). Therefore, loss of 
mTOR  induces  a  significant  shift  toward  the  expression  of 
slower MHC isoforms, indicating contractile dysfunctions in all 
types of muscles.
mTOR deficiency more severely affects 
muscle functional properties than loss  
of raptor
To assess the functional consequences of mTOR inactivation 
in skeletal muscle, the muscle contractile performance was 
analyzed in response to nerve and/or muscle stimulation in 
9-wk-old mice (Table II). Both absolute maximum tetanic (Po) 
Results
Muscle-specific inactivation of mTOR leads 
to premature death
To investigate the role of mTOR in skeletal muscle develop-
ment and function, we developed a conditional mTOR gene 
inactivation strategy based on the Cre-loxP system (Fig. 1 A). 
mTOR
flox/flox mice were crossed with human skeletal muscle 
-actin (HSA)–Cre mice in which Cre-mediated recombination 
occurs in postmitotic myofibers but not in satellite cells (Nicole 
et al., 2003). At birth, Cre-positive mTOR
flox/flox (mTOR
) pups 
were viable, born at expected Mendelian ratios, and indistin-
guishable  from  their  control  littermates.  PCR  analysis  con-
firmed the efficient deletion of the mTOR allele specifically in 
skeletal muscle (Fig. 1 B). At 4 wk of age, the growth rate of 
mutant animals started to decrease (Fig. 1 C). By the age of 13 wk, 
mutant  mice  started  to  develop  spinal  deformity,  which  in-
creased with age in the form of kyphosis, a sign of muscle weak-
ness, accompanied by breathing difficulties and abnormal posture 
of the hindlimbs (Fig. 1 D). mTOR
 mice eventually died be-
tween 22 and 38 wk of age (Fig. 1 E).
mTOR
 mice develop a progressive MD
We next characterized muscles from mTOR
 mice by morpho-
metric and histological examinations. By the age of 6 wk, the 
body weight of mTOR
 mice was reduced by 10% compared 
with controls. This reduction could be attributed to a strong 
decrease in the mass of fast-twitch glycolytic muscles such as 
tibialis anterior (TA), gastrocnemius (GC), and plantaris (PLA; 
Table I). In contrast, the mass of the slow-twitch oxidative soleus 
muscle was not significantly affected by mTOR deficiency and 
was even increased after normalization to body weight. Of note, 
the weight of other organs remained unaffected in mTOR
 mice. 
At this age, fiber number was not significantly different between 
mTOR
 and control muscles (unpublished data), excluding hypo-
plasia as the cause of reduced mass in fast-twitch muscles. 
Table I.  mTOR
 mice exhibit reduced body weight associated with a strong reduction in the mass of fast-twitch glycolytic muscles
Variable Control mTOR
 % Control
Body weight (g) 17.41 ± 1.05 15.85 ± 1.37
a 91.0
Soleus weight (mg) 4.93 ± 0.64 5.00 ± 0.61 101.4
Soleus/body weight (mg/g) 0.28 ± 0.03 0.32 ± 0.03
b 114.3
TA weight (mg) 30.93 ± 3.56 24.54 ± 2.29
a 79.3
TA/body weight (mg/g) 1.78 ± 0.22 1.55 ± 0.04
a 87.1
GC weight (mg) 71.13 ± 5.23 56.27 ± 4.79
a 79.1
GC/body weight (mg/g) 4.09 ± 0.26 3.55 ± 0.07
a 86.8
PLA weight (mg) 10.81 ± 0.53 8.37 ± 0.85
a 77.4
PLA/body weight (mg/g) 0.62 ± 0.03 0.53 ± 0.06
a 85.5
Liver (mg) 868.26 ± 53.77 851.84 ± 102.75 98.1
Liver/body weight (mg/g) 50.05 ± 4.50 53.69 ± 3.40 107.3
Fat pad weight (mg) 295.78 ± 40.15 286.73 ± 30.12 96.9
Fat pad/body weight (mg/g) 16.98 ± 1.90 18.08 ± 1.15 106.9
Heart weight (mg) 120.62 ± 9.49 114.17 ± 9.07 94.7
Heart/body weight (mg/g) 6.95 ± 0.68 7.22 ± 0.50 103.9
Values are for 6-wk-old control and mTOR
 female mice. Fat data includes ovarian, uterine, and retroperitoneal fat pads. Data indicate mean ± SD (n > 5 
mice/group).
aP < 0.01.
bP < 0.05.JCB • VOLUME 187 • NUMBER 6 • 2009   862
caused by a loss of contractile muscle mass. In contrast, loss 
of raptor in muscles from age-matched RAmKO mice did not 
significantly alter sPo.
Moreover, mTOR
 muscles contracted and relaxed slowly 
as shown by the increased time to peak twitch tension (TTP) 
and one-half relaxation time (RT50%), which is consistent with 
the  MHC  distribution  toward  slower  isoforms.  Furthermore, 
mTOR
  soleus  muscle  was  twofold  less  resistant  to  fatigue 
(F20%) than control muscle, whereas RAmKO muscles were 
more resistant to fatigue (Bentzinger et al., 2008).
We next tested whether mTOR or raptor deficiency im-
pacts resistance to contraction-induced injury in situ by subjecting 
and twitch (Pt) forces were significantly decreased in mTOR
 
soleus and TA muscles compared with control muscles. Stim-
ulation of mTOR
 TA directly or via its nerve gave rise to a 
similar reduction in absolute Po, indicating that neurotrans-
mission was not altered in mTOR
 mice. The reduction in 
force production was more pronounced in mTOR
 TA be-
cause of the large decrease in muscle mass observed in fast-
twitch  muscles.  Indeed,  when  Po  was  normalized  for  TA 
muscle mass or for soleus muscle CSA, the specific maxi-
mum tetanic force (sPo) was reduced to the same extent (by 
30%) in both mTOR
 TA and soleus muscles, further indi-
cating  that  muscle  weakness  of  mTOR
  mice  is  not  only 
Figure  2.  mTOR
  mice  develop  a  progres-
sive MD. (A) Analysis of the mean fiber CSA 
in TA and soleus muscles from 6-wk-old mice 
(n  =  4).  (B)  H&E-stained  transverse  sections 
of TA, soleus, and diaphragm (DIA) muscles 
from control and mTOR
 mice. Degeneration 
with phagocytosis and mononuclear cell infil-
tration (green arrows), variation in fiber size 
with  small  atrophic  fibers  (yellow  arrows), 
interfiber  connective  tissue  (thin  arrows),  re-
generated muscle fibers with centrally located 
nuclei (black arrows), fibrosis (asterisk), and 
fatty infiltration (red arrows) are shown. Adipo-
genic differentiation was confirmed by oil red 
O staining as shown in the inset. Bar, 50 µm. 
(C)  Percentage  of  centrally  nucleated  fibers 
(CNF) increases with age in mTOR
 muscles. 
(D) Relative mRNA levels of MyH8, IGF-II, and 
myogenin  in  mTOR
  muscles  from  6-wk-old 
mice. (E–G) Graphs show the percentage dis-
tribution of MHC isoforms I, 2B, 2X, and 2A in   
soleus (E), TA (F), and PLA (G) muscles from   
6-wk-old control and mTOR
 mice. (C–G) n = 5   
sample sets. *, P < 0.05; **, P < 0.01; ***,   
P < 0.001. Data indicate mean ± SEM.863 mTOR deficiency leads to severe muscular dystrophy • Risson et al.
of  its  autosomal  homologue  utrophin  (Tinsley  et  al.,  1998). 
mTOR
 muscles also showed decreased expression of several 
DGC components, including -sarcoglycan and -dystroglycan, 
and induction of utrophin (Fig. 3 A and Table S1). Dystro-
phin content was further reduced in mutant soleus and TA mus-
cles from 11-wk-old mice, reaching 13 and 17% of the levels 
in control muscles (Fig. S2 and Table S2). In contrast, expres-
sion of caveolin-3 and calpain 3, whose deficiency leads to ad-
ditional forms of MD (Watchko et al., 2002), was significantly 
up-regulated.
The DGC plays a major role in regulating membrane in-
tegrity, and its loss leads to sarcolemmal fragility and perme-
ability (Straub et al., 1997). However, the overall sarcolemmal 
integrity of quiescent mTOR
 muscle fibers was maintained 
because rare muscle fibers exhibited Evans blue dye uptake 
(Fig. 3 B), and elevated creatine kinase serum levels were not 
detected in mTOR
 mice (not depicted). Importantly, immuno-
fluorescence analysis showed that residual dystrophin was still 
present along the sarcolemma of the noncentronucleated fibers 
(Fig. 3 C). Thus, it is likely that residual DGC may modulate 
membrane damage in mTOR
 muscles.
TA muscles to a series of high stress muscle-eccentric contrac-
tions. Importantly, loss of mTOR but not of raptor resulted in 
increased force deficit, indicating a higher susceptibility to 
injury of mTOR
 muscle. Collectively, these data show that 
mTOR deficiency more severely affects muscle contractile 
properties than loss of raptor.
mTOR
 muscles display reduced levels of 
DGC components and induction of utrophin
Most forms of MD arise from mutations in the DGC, which 
provides a physical link between the extracellular matrix and 
the intracellular cytoskeleton (Durbeej and Campbell, 2002). 
Force deficits after eccentric contractions are a functional hall-
mark of dystrophin-deficient muscle (Watchko et al., 2002). 
This observation prompted us to examine dystrophin levels in 
mTOR
 muscles. Western blot analysis revealed a strong reduc-
tion in muscle dystrophin content in 6-wk-old mTOR
 mice 
(Fig. 3 A and Table S1). In Duchenne MD (DMD) and the mdx 
mouse model for DMD, loss of dystrophin is associated with the 
concurrent down-regulation of other DGC members (Ohlendieck 
and Campbell, 1991) and with a compensatory up-regulation 
Table II.  Comparison of muscle contractile properties between mTOR
 and RAmKO mice
Mice Control mTOR
/RAmKO % Control
Soleus muscle
mTOR
  Mass (mg) 7.6 ± 0.4 7.5 ± 0.3 98.7
  Po (mN)
a 141.6 ± 33.2 104.3 ± 24.0
c 73.6
  sPo (mN/mm
2)
a 187.9 ± 42.0 134.5 ± 37.1
c 71.6
  Pt (mN)
a 26.4 ± 3.7 16.2 ± 4.1
d 61.4
  TTP (ms)
a 82.7 ± 11.1 171.5 ± 73.8
d 207.4
  RT50% (ms)
a 131.7 ± 45.3 375.4 ± 228.2
c 285.0
  F20% (ms)
a 85.1 ± 14.5 41.1 ± 18.9
d 48.3
Raptor
  Mass (mg) 7.1 ± 0.9 6.5 ± 0.9 90.9
  Po (mN)
a 155.6 ± 24.6 141.7 ± 11.0 91.0
  sPo (mN/mm
2)
a 211.5 ± 38.7 212.4 ± 19.3 100.4
TA muscle
mTOR
  Mass (mg) 37.5 ± 1.2 32.7 ± 2.2
d 87.2
  Po (mN)
a 536.3 ± 100.7 332.0 ± 55.4
d 61.9
  Po (mN)
b 567.1 ± 79.1 359.7 ± 34.8
d 63.4
  sPo (mN/mg)
b 15.1 ± 2.2 11.0 ± 1.4
c 73.0
  Pt (mN)
b 106.4 ± 25.8 60.5 ± 9.5
d 56.7
  TTP (ms)
b 31.5 ± 2.4 42.4 ± 9.3 134.6
  RT50% (ms)
b 33.2 ± 3.8 58.0 ± 10.9
d 174.7
  Deficit (%)
b 12.7 ± 5.0 56.0 ± 12.9
d 340.9
Raptor
  Mass (mg) 41.0 ± 2.4 36.2 ± 1.7
d 88.5
  Po (mN)
b 607.1 ± 35.7 497.0 ± 55.2
d 81.9
  sPo (mN/mg)
b 14.9 ± 1.4 13.8 ± 1.8 92.5
  Deficit (%)
b 12.0 ± 3.5 12.2 ± 7.3 1.5
Muscle contractile properties of 9-wk-old mTOR and raptor mice were assessed by recording isometric forces in response to electrical stimulation. The following data 
were measured: muscle mass, Po, sPo, Pt, TTP, RT50%, time taken for maximal twitch tension to fall by 20% (F20%), and the percentage of force deficit following 
repetitive eccentric contractions (deficit). The data indicate mean ± SD (n > 4 mice/group).
aMuscle electrical stimulation.
bNerve electrical stimulation.
cP < 0.05.
dP < 0.01.JCB • VOLUME 187 • NUMBER 6 • 2009   864
markers -skeletal actin and troponin T, it led to a rapid and 
strong down-regulation of the dystrophin protein. These re-
sults demonstrate that the mTOR cell autonomously regulates 
dystrophin levels.
We next assessed whether reduced dystrophin content re-
flects changes at the mRNA levels. In cultured mTOR
 myo-
tubes and muscles, mRNA levels for several DGC components 
were significantly reduced as compared with control levels, 
indicating possible transcriptional defects (Fig. 4, B and C). 
mTOR controls dystrophin expression in a 
cell-autonomous, rapamycin-resistant, and 
kinase-independent manner
To  gain  better  insight  into  the  regulation  of  dystrophin  by 
mTOR, we performed mTOR knockdown in primary myo-
tubes derived from mTOR
flox mice infected with Cre-expressing 
adenovirus (Fig. 4 A). Although mTOR inactivation in cul-
tured myotubes did not prevent terminal differentiation as 
shown by the induction of the late myogenic differentiation 
Figure 3.  Reduced DGC amount and utrophin 
induction in mTOR
 muscles. (A) Soleus, dia-
phragm, and TA muscle extracts from 6-wk-old 
mice were immunoblotted with the indicated 
antibodies to examine dystrophy-related pro-
tein levels. Black lines indicate that interven-
ing  lanes  have  been  spliced  out.  (B)  Rare 
Evans  blue–positive  fibers  can  be  detected 
in mTOR
 diaphragms from 30-wk-old mice. 
(C)  Dystrophin  immunostaining  (green)  and 
Hoechst staining (blue) on soleus muscle sec-
tions from 11-wk-old control and mTOR
 mice 
showing sarcolemmal localization of residual 
dystrophin. A higher magnification view (inset) 
shows that dystrophin expression is reduced in 
noncentronucleated fibers, whereas it is nor-
mal  in  regenerating  centronucleated  fibers. 
Bars, 50 µm.865 mTOR deficiency leads to severe muscular dystrophy • Risson et al.
We next determined whether dystrophin regulation in-
volved  rapamycin-sensitive  mTOR  functions  and  mTOR   
kinase activity. In cultured C2C12 myotubes and mouse soleus 
muscle,  neither  rapamycin  nor  Torin1  treatment  reduced 
dystrophin  mRNA  levels,  although  both  mTOR  inhibitors   
efficiently inhibited mTORC1 signaling (Fig. 4 E). Consis-
tently, overexpression of a rat mTOR wild type or mTOR 
kinase dead into the TA muscle of mTOR
 mice by in vivo 
DNA  electroporation  significantly  increased  dystrophin 
mRNA levels by 2.1 and 2.5 times, respectively, as compared 
with control (Fig. 4 F). In agreement with these observa-
tions, dystrophin levels were not reduced in muscles lacking 
raptor and rictor (Fig. 4 G). Collectively, these findings dem-
onstrate  that  mTOR  controls  dystrophin  expression  in  a   
In contrast, no change was detected for dysferlin, whereas 
caveolin-3 and utrophin were up-regulated.
Because mTOR was shown to interact and positively 
regulate the activity of the transcription factor YY1 in myo-
tubes (Cunningham et al., 2007) and YY1 was shown to bind 
the dystrophin promoter (Galvagni et al., 1998), we hypothe-
sized that mTOR should bind to the dystrophin promoter.   
To  test  our  hypothesis,  we  performed  chromatin  immuno-
precipitation (ChIP) analysis on TA muscle from control mice 
(Fig. 4 D). We found that mTOR is bound to the promoter of 
the dystrophin gene at the same extent as RNA polymerase II, 
whereas it was not bound to the dysferlin promoter. These re-
sults strongly suggest that mTOR directly regulates the dys-
trophin promoter.
Figure 4.  mTOR controls dystrophin expres-
sion. (A) Time course for mTOR inactivation, 
dystrophin  down-regulation,  and  induction 
of terminal differentiation markers in cultured 
mTOR
flox myotubes. The myotubes were trans-
duced by CMV-GFP or CMV-Cre adenovirus 
on differentiation day 1 (dd1), harvested at 
a different time point after differentiation, and 
immunoblotted with the indicated antibodies. 
(B) Relative mRNA levels of mTOR and the indi-
cated DGC components in mTOR
flox myotubes 
transduced by Ad-Cre (n = 3). (C) Relative mRNA 
levels of mTOR and the indicated dystrophy- 
related genes in muscles from 6-wk-old mice   
(n = 5). (D) Detection of mTOR on the dystrophin 
promoter  by  ChIP  assay.  Antibodies  against 
mTOR (lane 1), normal mouse IgG (lane 2), 
or RNA polymerase 2 (lane 3) were used to 
immunoprecipitate (IP) a mouse TA chromatin 
extract. The precipitated DNA was analyzed 
by PCR using primers for the dystrophin (top) 
or dysferlin (bottom) promoter. (E, top) West-
ern blot analysis showing the phosphorylation 
status of S6 protein in C2C12 myotubes in the 
absence () or presence (+) of 20 nM rapa-
mycin or 250 nM Torin1 for 48 h from differ-
entiation day 4. For soleus muscle, C57BL/6 
mice  were  daily  injected  intraperitoneally 
with 2.5 mg/kg rapamycin or vehicle for 8 d. 
(bottom) mRNA levels for the indicated DGC 
components in C2C12 myotubes and soleus 
muscle in absence or presence of the indicated 
mTOR inhibitors. (F) Relative mRNA levels of 
dystrophin in the TA muscle fibers of mTOR
 
mice 12 d after in vivo coelectroporation of 
rat wild-type (wt) or kinase-dead (kd) mTOR 
and pRNAT-GFP vector. Graphs show means 
versus pcDNA3-electroporated control (n = 5 
mice/group). (G) Western blot analysis show-
ing dystrophin protein levels in soleus muscle 
from  14-wk-old  RAmKO  and  RImKO  mice.   
*, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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phosphorylation of S6 and PKB/Akt, respectively. Decreased 
phosphorylation of S6 was consistent with down-regulation of 
mTORC1. Surprisingly, phosphorylation of the mTORC2 down-
stream target PKB/Akt was strongly increased on Ser473. This 
observation implies the existence of a distinct kinase from mTOR 
able to phosphorylate PKB/Akt at this residue as previously sug-
gested (Bentzinger et al., 2008). In addition, PDK1-dependent 
phosphorylation of PKB/Akt on Thr308 was also increased. In-
creased PKB/Akt activation in mTOR
 muscle could result from 
the suppression of the inhibitory feedback from S6K on insulin 
signaling. The negative feedback involves S6K phosphorylation 
of IRS-1 leading to its degradation, thereby suppressing insulin 
signaling (Um et al., 2006). Consistent with the loss of negative 
feedback, IRS-1 protein levels were strongly increased in 
mTOR
 muscles (Fig. 5 A). Interestingly, hyperactivation of 
PKB/Akt was accompanied by an up-regulation of its protein 
rapamycin-resistant  and  kinase-independent  manner  inde-
pendently of raptor and rictor.
MD in mTOR
 mice is associated with a 
down-regulation of mTORC1 signaling and 
hyperactivation of PKB/Akt
We next investigated the consequences of mTOR depletion on 
signal transduction in mutant muscles. Western blot analysis re-
vealed that mTOR protein level was strongly decreased in mu-
tant muscles (Fig. 5 A and Table S3). Residual mTOR expression 
likely arose from nonmuscle cells as well as from cells in which 
the mTOR allele was not recombined, including newly repaired 
muscle fibers and satellite cells. In contrast, expression of the 
specific mTORC1 and mTORC2 components, raptor and rictor, 
respectively, remained unchanged. mTORC1 and mTORC2 ac-
tivity in mutant muscles was next assessed by monitoring 
Figure 5.  Signal transduction in mTOR
 muscles. (A) Muscle extracts from 6-wk-old mice were immunoblotted with the indicated antibodies to examine 
mTORC1 and mTORC2 signaling in soleus and TA muscles. Black lines indicate that intervening lanes have been spliced out. (B and C) Immunofluores-
cence staining for total PKB/Akt (B) and P-PKB/Akt (C; green) and Hoechst staining (blue) on control and mTOR
 soleus muscle sections. Bars, 50 µm.   
(D) Relative mRNA levels of MuRF1 and MAFbx in mTOR
 soleus and TA muscles. **, P < 0.01; ***, P < 0.001. Data indicate means versus control ± SEM 
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Loss of mTOR leads to increased muscle 
glucose uptake and glycogen accumulation
Inactivation of GSK3 by PKB/Akt was shown to promote 
glycogen synthesis (Cross et al., 1997), suggesting that gly-
cogen synthesis might be increased in mTOR
 muscles. Con-
sistent with this, periodic acid Schiff staining demonstrated 
that  glycogen  content  was  strongly  increased  in  mTOR
 
muscles (Fig. 6 A). Quantification of glycogen levels showed 
a 2.3-, 7.5-, and 4.3-fold increase in mTOR
 soleus, TA, and 
PLA muscles, respectively, as compared with control mus-
cles (Fig. 6 B). We next assessed whether increased glycogen 
content in mTOR
 muscles could also result from diminished 
glycogenolysis and glycolytic capacity. Indeed, the activity 
of glycogen phosphorylase (GP), hexokinase, phosphofruc-
tokinase (PFK), pyruvate kinase (PK), and lactate dehydrog-
enase  (LDH)  was  consistently  reduced  in  mTOR
  soleus 
(Fig. 6 C) and TA muscles (Fig. 6 D). In addition, reduced 
activity of glycolytic enzymes in mTOR
 muscles was asso-
ciated with a significant reduction in their expression (Fig. 6 E). 
level, a feature that has been previously reported in both DMD 
and mdx muscles, irrespective of the muscle pathogenic state 
(Dogra et al., 2006). Consistently, immunostaining for PKB/Akt 
(Fig. 5 B) and P-PKB/Akt
S473 (Fig. 5 C) was stronger in regener-
ating centronucleated and nonregenerating mTOR
 muscle 
fibers compared with control fibers.
PKB/Akt has been shown to phosphorylate and inactivate 
the forkhead box transcription factors FoxO1 and FoxO3, 
thereby blocking the transcriptional up-regulation of the atrophy-
related genes MAFbX and MuRF1 (Stitt et al., 2004). Consis-
tent with PKB/Akt hyperactivation, both MaFbX and MuRF1 
mRNA were down-regulated in mTOR
 muscles (Fig. 5 D), in-
dicating that the atrophy observed in mutant muscle is not asso-
ciated with activation of the ubiquitin proteasome pathway. In 
addition,  PKB/Akt  phosphorylates  and  inactivates  GSK3,   
an inhibitory kinase of glycogen synthase (Cross et al., 1997). 
Accordingly, phosphorylation of the regulatory residues Ser9 in 
GSK3 and/or Ser21 in GSK3 was increased in mTOR
 mus-
cles (Fig. 5 A).
Figure 6.  Altered glucose usage and glyco-
gen accumulation in mTOR
 muscle. (A) Repre-
sentative periodic acid Schiff staining of soleus 
(SOL), PLA, GC, and TA muscle sections from 
6-wk-old mice showing glycogen accumulation 
in mTOR
 muscles. Bar, 400 µm. (B) Quan-
tification of muscle glycogen content (n = 5   
sample  sets).  (C  and  D)  GP  and  glycolytic   
enzyme activity in soleus (C) and TA (D) mus-
cles (control, n = 5; mTOR
, n = 4). (E) Rela-
tive  mRNA  levels  of  the  indicated  glycolytic   
enzymes in mTOR
 muscles (n = 5 sample sets). 
(F) Quantification of intramuscular glucose-6-
phosphate (G6P) in control and mTOR
 mice. 
(G) Quantification of intramuscular lactate in 
control and mTOR
 mice. (H) Enhanced basal 
glucose uptake in isolated soleus muscle from 
5-wk-old control and mTOR
 mice (n = 5–6 
mice). (F and G) n = 8 sample sets. HK, hexo-
kinase. *, P < 0.05; **, P < 0.01; ***, P < 
0.001. Data indicate mean ± SEM.JCB • VOLUME 187 • NUMBER 6 • 2009   868
metabolic properties of mTOR
 soleus muscle. Recent evi-
dence indicates that mTORC1 controls mitochondrial bio-
genesis  and  respiration,  notably  via  YY1  and  PGC1 
(Cunningham et al., 2007; Bentzinger et al., 2008). In agree-
ment, measurement of citrate synthase activity indicated a 
twofold reduction in mitochondrial content (Fig. 7 C), and 
the expression of several genes involved in oxidative metabo-
lism was markedly reduced in mTOR
 soleus muscle (Fig. 7, 
D and E).
To investigate the consequences of mTOR inactivation 
on intrinsic oxidative capacities in soleus muscles, we ana-
lyzed  mitochondrial  respiration  and  function  in  saponin-
skinned  fibers  with  nonlimiting  amounts  of  substrate  and 
oxygen. Consistent with decreased mitochondrial content in 
mTOR
 soleus, the rate of oxygen consumption in muscle was 
diminished both in the absence (basal) or presence (maximal) 
of ADP, whereas the ratio of maximal to basal respiration (ac-
ceptor control ratio) was increased (Fig. 7 F). These results in-
dicate that the lack of mTOR in soleus muscles reduced the 
maximal capacity of oxidative phosphorylation, whereas the 
Consistent with diminished glycolytic flow, reduced levels   
of  glucose-6-phosphate  (Fig.  6  F)  and  lactate  (Fig.  6  G)   
were  measured  in  mTOR
  muscles.  Importantly,  this  de-
crease was not caused by defects in glucose uptake because 
basal  2-deoxyglucose  uptake  was  even  increased  1.8-fold 
into isolated mTOR
 soleus muscle compared with controls 
(Fig. 6 H).
mTOR deficiency in muscle alters 
mitochondrial regulation and  
oxidative capacity
At the macroscopic level, mTOR
 muscles appeared paler 
than  control  muscles.  This  was  particularly  striking  in 
mTOR
 soleus muscles, which lacked the red color charac-
teristic of oxidative muscles (Fig. 7 A). Moreover, staining 
for  succinate  dehydrogenase,  a  marker  of  mitochondrial 
complex II, was weak in mTOR
 soleus fibers to the extent 
that the difference in oxidative activity classically observed 
between fiber types was barely detectable (Fig. 7 B). These 
observations suggested changes to have taken place in the 
Figure 7.  Impaired oxidative metabolism in 
mTOR
 soleus muscle. (A) mTOR
 soleus mus-
cle is paler than control muscle. (B) Succinate 
dehydrogenase histochemical staining demon-
strating alterations of oxidative metabolism in 
mTOR
 soleus muscle from 6-wk-old mice. Oxi-
dative and glycolytic fibers are indicated by   
red and yellow arrows, respectively. Bar, 100 µm.   
(C) Decreased citrate synthase (CS) activity 
in mTOR
 soleus muscle (n = 5 sample sets). 
(D) Relative mRNA levels of genes involved in 
oxidative energy production in mTOR
 soleus 
muscle (n = 5 sample sets). (E) Western blot 
analysis  showing  reduced  protein  levels  for 
myoglobin, cytochrome c (cytc), and respira-
tory  chain  components  (CI–CV)  in  mTOR
 
soleus  muscle.  Equal  protein  loading  was   
controlled by measuring total protein content 
and  Coomassie  blue  staining.  (F)  Effect  of 
mTOR depletion on mitochondrial respiration in   
saponin-skinned fibers from soleus muscles from 
6-wk-old mice with glutamate and malate as 
substrates. The following data were measured: 
basal rate of mitochondrial oxygen consump-
tion in the absence of ADP (Vo), maximal rate 
of  oxygen  consumption  in  the  presence  of   
2  mM  ADP  (Vmax),  and  acceptor  control 
ratio (ACR; control, n = 15; mTOR
, n = 8).   
(G) Effect of mTOR depletion on mitochondria 
sensitivity  for  ADP  in  saponin-skinned  fibers 
from soleus muscles. The apparent Km for ADP 
was measured in the absence and presence of 
20 mM creatine (control, n = 8; mTOR
, n = 5).   
(H) Intramuscular ATP levels in muscles from 
control and mTOR
 mice (n = 8 sample sets). 
##, P < 0.01 (for control with creatine versus 
control  without  creatine);  **,  P  <  0.01  (for 
mTOR
 without creatine versus control without 
creatine). Data indicate mean ± SEM.869 mTOR deficiency leads to severe muscular dystrophy • Risson et al.
Discussion
To determine the physiological role of mTOR in postnatal skel-
etal  muscle,  we  generated  muscle-specific  mTOR  knockout 
mice (mTOR
) using HSA-Cre mice expressing Cre in post-
mitotic myofibers but not in satellite cells (Nicole et al., 2003). 
Our  study  reveals  that  mTOR  deficiency  in  skeletal  muscle 
leads to metabolic changes resulting in glycogen accumulation. 
Specifically, these changes include an increase in glucose up-
take and glycogen synthesis associated with reduced glycogen 
breakdown through glycogenolysis and glycolytic and oxida-
tive pathways. Our in vivo data support and extend findings of 
previous in vitro studies (Hardwick et al., 1999; Peng et al., 
2002; Edinger et al., 2003; Schieke et al., 2006; Cunningham 
et al., 2007). Indeed, mammalian cells transfected with mTOR 
or raptor short hairpin RNAs or treated with rapamycin demon-
strate altered glycolysis and oxidative metabolism associated 
with a parallel change in gene expression. In addition, mTOR 
inhibition  by  rapamycin  abrogated  the  PKB/Akt-mediated   
induction of glycolytic enzymes in a constitutive PKB/Akt   
murine model of prostate intraepithelial neoplasia (Majumder 
et al., 2004). Finally, mTOR and raptor have been shown to   
directly regulate mitochondrial biogenesis and oxidative func-
tions  through  the  control  of  a YY1–PGC1  transcriptional 
complex (Cunningham et al., 2007). Our study further reveals 
that deficiency in intracellular energy transfer could be an addi-
tional  mechanistic  basis  for  the  mitochondrial  alterations  in 
mTOR
 muscle.
However,  intramuscular  ATP  levels  were  preserved  in 
mTOR
 mice. Similarly, ATP concentration was not changed in 
cells treated with rapamycin, despite lower rates of oxygen con-
sumption and glycolysis (Cunningham et al., 2007). Although 
glucose metabolism was altered, basal glucose uptake and gly-
cogen synthesis were increased in mTOR
 muscle. These effects 
coupling  efficiency  between  oxidation  and  phosphorylation 
was improved. Mitochondrial function depends on its sensitiv-
ity to ADP and creatine, which differs in oxidative and glyco-
lytic muscle fibers (Kuznetsov et al., 1996). In oxidative fibers, 
the  apparent  Km  (Michaelis–Menten  constant)  for ADP  is 
high and is decreased by creatine as a consequence of the 
functional coupling of mitochondrial creatine kinase to ATP 
production  and  energy  transfer  (Fig.  7  G).  Surprisingly,  in 
mTOR
  soleus  muscle  fibers,  the  apparent  Km  for  ADP   
was  unusually  low  and  remained  unaffected  by  creatine.   
Altogether, our findings demonstrate that loss of mTOR not 
only affects mitochondrial biogenesis and oxygen consump-
tion, but additionally leads to profound changes into the mito-
chondria metabolic properties of oxidative fibers, which share 
characteristics with those of glycolytic fibers. However, intra-
muscular ATP concentrations were not significantly reduced 
in mTOR
 muscles (Fig. 7 H).
mTOR deficiency in muscle does not impair 
whole body glucose homeostasis
We next investigated the effect of mTOR deficiency in skeletal 
muscle on whole body glucose homeostasis. In the fasting state, 
mTOR
 mice had significantly lower glucose levels (Fig. 8 A), 
which is possibly the result of increased basal glucose uptake in 
skeletal muscle (Fig. 6 H). However, the glucose and insulin 
concentrations in the fed state and the insulin level in fasting 
mice were not statistically different between mTOR
 and con-
trol mice (Fig. 8, A and B), suggesting that glucose tolerance 
and insulin sensitivity were not affected. Consistent with this, 
mTOR
 and control mice showed similar responses during the 
glucose tolerance test (Fig. 8 C) and the insulin tolerance test 
(Fig. 8 D). Collectively, these results indicate that mTOR func-
tions in skeletal muscle are not crucial in controlling whole 
body glucose homeostasis.
Figure  8.  Glucose  homeostasis  and  insulin 
sensitivity in mTOR
 mice. (A) Fasting and fed 
blood glucose concentrations in mTOR
 and 
control male mice. (B) Fasting and fed serum 
insulin concentrations in mTOR
 and control 
male mice (n = 7 mice/group). (C) Glucose tol-
erance test on male mice (n = 15 mice/group). 
(D) Insulin tolerance test on mTOR
 and control 
mice (n = 8 mice/group). **, P < 0.01. Data 
indicate mean ± SEM.JCB • VOLUME 187 • NUMBER 6 • 2009   870
of mTOR
 muscles are similar to mdx muscle, as they also ex-
hibit a contraction-induced force deficit (Watchko et al., 2002). 
In addition, skeletal muscle from mdx mice generally shows 
increased mass attributed to the ongoing cycle of degeneration 
and regeneration, producing larger but weaker muscle fibers 
(Watchko et al., 2002).
However, mTOR
 muscles do not display increased sarco-
lemmal permeability, one of the most characteristic and early 
features of muscles lacking dystrophin (Straub et al., 1997), al-
though  sarcolemmal  fragility  of  mTOR
  muscle  is  demon-
strated  by  the  great  force  deficits  associated  with  eccentric 
contractions. Importantly, dystrophin levels in mTOR
 muscles 
reach 10–20% of those in control muscles, and levels of DGC 
components are only mildly decreased, whereas the entire pro-
tein complex is lost in DMD and mdx muscle (Ohlendieck and 
Campbell,  1991).  Therefore,  it  is  likely  that  residual  sarco-
lemmal DGC or utrophin–glycoprotein complex modulate mem-
brane damage of mTOR
 muscles (Peter et al., 2009). In line 
with this, studies on mdx mice treated with gentamicin have 
demonstrated that 10–20% of dystrophin levels are sufficient to 
restore the assembly of DGC and can afford significant but not 
complete protection against injury (Barton-Davis et al., 1999).
We also provide evidence that the reduction of dystrophin 
is based on a reduction of transcripts. Moreover, we show that 
mTOR binds the dystrophin promoter, strongly suggesting that 
this reduction is controlled at the transcriptional level. mTOR 
controls the transcription of many genes (Peng et al., 2002). In 
particular, mTOR interacts with and positively regulates YY1 
transcriptional activity to activate mitochondrial gene expres-
sion  in  myotubes  (Cunningham  et  al.,  2007).  Interestingly, 
YY1 has also been shown to bind and regulate the dystrophin 
promoter (Galvagni et al., 1998). Therefore, it is tempting to 
speculate that mTOR may positively modulate YY1 function 
in myotubes to drive dystrophin expression. In addition, our 
findings that mTOR regulatory function on dystrophin tran-
scription is insensitive to rapamycin are consistent with the ob-
servation  that  mTOR  interacts  with YY1  independently  of 
rapamycin and that dystrophin is not down-regulated in RAmKO 
muscles.  Interestingly,  using  rapamycin, Akt  activation  was 
shown to prevent the force deficit induced in mdx muscles by 
eccentric contractions independently of mTOR (Blaauw et al., 
2008). Our finding that mTOR regulates dystrophin expression 
in a rapamycin-resistant manner may provide an explanation 
for this discrepancy.
We also provided evidence that mTOR kinase activity is 
not required to regulate dystrophin, thus further extending the 
list of catalytic independent mTOR functions. Indeed, mTOR 
was shown to regulate IGF-II expression and myogenesis via a 
kinase-independent mechanism (Erbay and Chen, 2001; Erbay 
et al., 2003).
Collectively, our data point toward a new and specific role 
of mTOR in the regulation of dystrophin expression in a way 
that is not strictly dependent on mTORC1 and mTORC2. Of 
note, down-regulation of dystrophin in mTOR
 muscle can-
not be attributed to the loss of both mTORC1 and mTORC2 
functions because DmKO mice neither display a more severe 
phenotype than RAmKO nor the characteristic Akt protein 
are probably mediated by the hyperactivation of PKB/Akt   
in mutant muscles. Increased basal glucose uptake in muscle 
could possibly contribute to the lower basal glucose levels in 
mTOR
 mice. However, glucose tolerance and insulin sensitiv-
ity were not affected in mTOR
 mice, indicating that muscle 
mTOR does not play a crucial role in controlling whole body 
glucose homeostasis.
Decreased oxidative capacity, altered mitochondrial reg-
ulation, glycogen accumulation, and hyperactivation of PKB/
Akt were also reported in RAmKO but not in RImKO muscles 
(Bentzinger et al., 2008), indicating that mTORC1 disruption 
likely accounts for these changes in mTOR
 muscles. Although 
glycolytic pathways were not investigated in RAmKO mice, 
our observations strongly suggest that glycolytic capacity is 
also reduced in this model. Hyperactivation of PKB/Akt in 
mTOR
 muscle is associated with reduced mTORC1 signaling 
and increased IRS-1 levels, indicating that this feature results 
from the loss of the well-documented S6K-mediated inhibitory 
feedback on IRS-1 (Um et al., 2006) as observed in RAmKO 
muscle (Bentzinger et al., 2008). In addition, the persistence of 
PKB/Akt  phosphorylation  on  Ser473  in  mTOR
  muscle  is 
reminiscent of muscle lacking both raptor and rictor but still 
containing mTOR. Thus, our observations confirm and extend 
the findings by Bentzinger et al. (2008) that skeletal muscles 
express a kinase distinct from mTOR that is able to phosphory-
late PKB/Akt on this site. In line with this, additional kinases, 
designated as PDK2 kinases, have been proposed to phosphory-
late Akt  on  Ser473  (Bayascas  and Alessi,  2005).  Despite   
the hyperactivation of PKB/Akt in raptor-deficient muscles, 
RAmKO mice exhibited altered glucose tolerance (Bentzinger 
et al., 2008). It is not clear at present how raptor and rictor 
(Kumar et al., 2008) but not mTOR inactivation in muscle gen-
erates glucose intolerance.
In addition, we show that loss of mTOR in muscle results 
in a progressive muscle myopathy similar to that observed in 
RAmKO mice (Bentzinger et al., 2008). However, muscle pathol-
ogy is exacerbated and extended to all types of muscles in mTOR
 
mice. For example, mTOR
 muscles contain up to 35% of regen-
erating fibers, whereas the proportion of regenerating fibers 
remained very low in RAmKO mice. Moreover, mTOR deficiency 
severely affects the functional properties of slow- and fast-twitch 
skeletal muscles, whereas the contractile properties of the fast 
glycolytic extensor digitorum longus muscle were mainly spared 
in RAmKO mice. Finally, the sPo remained unaltered in muscles 
from RAmKO mice, whereas it is reduced by almost 30% in 
mTOR
 muscles, thus demonstrating that muscle weakness of 
mTOR
 mice is not only caused by a loss of muscle mass.
A possible explanation for the more severe myopathy in 
mTOR
 muscle is our finding that these muscles additionally 
exhibit reduced levels of both dystrophin and the entire DGC, a 
feature that is observed neither in RAmKO nor RImKO mus-
cles. Consistently with this finding, mTOR
 muscles display 
several features reminiscent of mdx and DMD muscles. At the 
molecular level, these include the up-regulation of utrophin 
(Tinsley et al., 1998), caveolin-3 (Repetto et al., 1999), and 
PKB/Akt protein levels (Acharyya et al., 2005; Dogra et al., 2006; 
Peter and Crosbie, 2006). Finally, the functional characteristics 871 mTOR deficiency leads to severe muscular dystrophy • Risson et al.
protease inhibitors) then transferred to a 2% formaldehyde solution for 
15  min  at  37°C.  Reactions  were  stopped  by  addition  of  glycine  at 
0.125 M final and incubation at 25°C for 5 min. After a PBS wash, mus-
cles were crushed in lysis buffer A (10 mM Tris-HCl, pH 7.9, 85 mM KCl, 
0.5% NP-40, and protease inhibitors). The mixture was homogenized by 
20 strokes of Dounce followed by a 5-min spin at 5,000 rpm at 4°C. The 
pellet was resuspended in lysis buffer B (50 mM Tris-HCl, pH 8, 10 mM 
EDTA, 1% SDS, and protease inhibitors) incubated on ice for 10 min fol-
lowed by a 5-min centrifugation at 5,000 rpm at 4°C. The supernatant 
was sonicated in a Bioruptor (Diagenode) for 15 min (medium; 30 s/30 s 
cycles). The size of chromatin fragment was checked to be in the range of 
300–500-bp length on an agarose gel after de–cross-linking. ChIP was 
performed using the EZ Magna ChIP kit (Millipore) with 200 µg chromatin 
and 20 µg antibody.
The antibodies used were mTOR (Cell Signaling Technology), normal 
mouse IgG (12–371; Millipore), and anti-RNA Pol2 CTD4H8 (05-623B; 
Millipore). PCR conditions were optimized for each couple of primers. 
The  primers  used  were  5-AGTTGAACATTATTTGAACT-3  and  5-ACT-
GAGTGAGTCAACATAGT-3 for the dystrophin promoter and 5-ACAGT-
CAGGGAAGGAAGCAA-3 and 5-CCTTCCACCTCTGTTCAGGA-3 for 
the dysferlin promoter.
Muscle histology, immunohistochemistry, morphometric  
measurements, and imaging
Skeletal muscles were collected, embedded in tragacanth gum, and quickly 
frozen in isopentane cooled in liquid nitrogen. 10-µm-thick sections were 
obtained from the middle portion of frozen muscles and processed for histo-
logical and immunohistochemical analysis according to standard proto-
cols. The fiber CSA and the number of centrally nucleated fibers were 
determined for three consecutive H&E-stained sections from at least four 
animals using Metamorph software (version 6.3; MDS Analytical Technolo-
gies). For immunostaining, cross sections were fixed in acetone at 20°C 
permeabilized with 0.1% Triton X-100/PBS, and incubated with specific 
primary antibody followed by Alexa Fluor 488–labeled secondary anti-
bodies (Invitrogen).
The following primary antibodies were used: dystrophin (Dys2; 
Novocastra), Akt (Cell Signaling Technology), and P-Akt (Cell Signaling Tech-
nology). For vital staining with Evans blue dye, the dye was resuspended 
in PBS at 1 mg/0.1 ml/10 g body wt and injected intraperitoneally. Mus-
cles were collected after 24 h, and frozen sections were rinsed in PBS and 
examined by fluorescence microscopy.
Confocal microscopy was performed using a spectral confocal 
laser-scanning  microscope  (TCS  SP5;  Leica)  on  an  upright  microscope 
(DM6000 B; Leica). Confocal software (LAS AF; Leica) was used for acqui-
sition with a Plan Apo 63× NA 1.4 oil objective (HCX; Leica). Fluores-
cence and light microscopy were performed using an upright microscope 
(Axioplan2; Carl Zeiss, Inc.) and 10× NA 0.3 (Ph1), 20× NA 0.5, or 40× 
NA 0.75 Plan NeoFluor objectives (Carl Zeiss, Inc.). Images were cap-
tured using a charge-coupled device monochrome camera (Coolsnap HQ; 
Photometrics) and MetaMorph software. For all imaging, exposure settings 
were identical between compared samples. All samples for microscopy 
were viewed at room temperature.
Quantitative real-time PCR and immunoblot analysis
Total RNA was isolated from cultured cells or muscle tissues using Trizol   
(Invitrogen). RNA was analyzed by quantitative real-time PCR using SYBR 
Green (Roche). The data were normalized to cyclophilin B, 2-microglobulin, 
and hypoxanthine–guanine phosphoribosyltransferase mRNA levels, which 
gave similar results. Western blots were performed as described previ-
ously (Ohanna et al., 2005). Primary antibodies used to study mTOR sig-
naling were obtained from Cell Signaling Technology. Primary antibodies 
against dystrophy-related proteins were obtained from Novocastra, and 
antibodies against troponin T were obtained from Sigma-Aldrich. Anti-
bodies against respiratory chain components, myoglobin, and cytochrome c 
were obtained from Mitosciences, Santa Cruz Biotechnolgoy, Inc., and BD, 
respectively.
Cell cultures
Primary cultures were derived from GC and TA muscles of 4-wk-old mTOR
flox 
mice as described previously (Ohanna et al., 2005). mTOR
flox myoblasts 
were differentiated in DME/Ham F12 containing 2% horse serum. The myo-
tubes were transduced by cytomegalovirus (CMV)-GFP or CMV-Cre adeno-
virus (Genethon) at 100 MOI on differentiation day 1 and harvested at 
different time points for gene expression analysis by quantitative real-time 
PCR or Western blotting. C2C12 myoblasts were differentiated in DME with 
2% horse serum and treated at differentiation day 4 with vehicle (DMSO), 
up-regulation observed in dystrophin-deficient muscles (Dogra 
et al., 2006). Evidence for mTOR functions that do not involve 
the contribution of these mTORCs is supported by a recent 
study showing that mTOR regulates terminal oligopyrimidine 
mRNA translation in a raptor- and rictor-independent manner 
(Patursky-Polischuk et al., 2009).
In conclusion, we demonstrate that the loss of mTOR in 
skeletal muscle leads to a severe myopathy, thereby further ex-
tending the list of disorders related to mTOR dysfunction. Our 
findings underscore the critical role of mTOR in regulating the 
genetic repertoire required for the appropriate maintenance of 
skeletal muscle integrity. About 40% of all myopathies have not 
yet been genetically characterized, whereas mTOR
 muscles 
recapitulate many of the features of a broad range of these dis-
orders, suggesting that alterations of mTOR-mediated processes 
could contribute to these disorders. Therefore, the importance 
of the mTOR pathway in maintaining muscle integrity provides 
new avenues of investigation in the diagnosis and therapy of 
skeletal muscle pathologies.
Materials and methods
Animals
The generation of the mTOR
neo embryonic stem (ES) clones used to function-
ally inactivate the mTOR gene was described previously (Gangloff et al., 
2004). In brief, a targeting vector was produced by introducing a loxP site 
upstream of the mTOR promoter region and a neo cassette flanked by two 
loxP sites in the intron preceding exon 6. To generate mTOR
neo ES cells, the 
construct was electroporated into 129SVJae ES cells, and G418-resistant 
clones were screened for homologous recombination by Southern blotting. 
For excision of the floxed PGK
neo cassette, the mTOR
neo ES cells were trans-
fected with 0.8 µg pEGFP-N1 (Takara Bio Inc.) and 0.2 µg pMC-Cre using 
transfection reagent (Effectene; QIAGEN). ES cells expressing EGFP were 
cultured in the presence and absence of G418. G418-sensitive colonies 
were analyzed by PCR. ES cells showing the selective deletion of the neo-
mycin resistance cassette and containing the mTOR floxed allele were in-
jected into C57BL/6J blastocysts to generate chimeric mice. Chimeric mice 
were mated with C57BL/6J mice to generate the heterozygous floxed mu-
tant (mTOR
+/flox) through germline transmission. Positive F1 offspring were 
identified by PCR and further backcrossed with C57BL/6J mice during five 
generations (F5 offspring). mTOR
+/flox mice were interbred to obtain a homo-
zygous  mutant  (mTOR
flox/flox).  mTOR
flox/flox  (control)  mice  were  bred  with 
HSA-Cre mice to generate Cre-positive mTOR
flox/flox (mTOR
) mice. ES cells 
and mice were genotyped by PCR.
The primers used to identify the mTOR flox allele were p2 (5-GCT-
CTTGAGGCAAATGCCACTATCACC-3) and p3 (5-TCATTACCTTCTCAT-
CAGCCAGCAGTT-3), and the primers to identify the recombined mTOR
 
allele were p1 (5-TTCATTCCCTTGAAAGCCAGTCTCACC-3) and p3. 
The animals were provided with mouse chow and water ad libitum in a   
restricted-access, specific pathogen–free animal care facility at the Ecole 
Normale  Superieure  of  Lyon  (Plateau  de  Biologie  Experimentale  de  la 
Souris). All procedures were performed in accordance with national and 
European legislation on animal experimentation.
In vivo electroporation of mTOR mutants
Expression vectors were injected into TA muscles (7 µg total DNA in 30 µl 
0.9% NaCl) of 6-wk-old mTOR
 female mice. Injected muscles were electro-
porated with 1-cm
2 plaque electrodes as described previously (Méjat et al., 
2005). The electroporated DNA mixtures contained 5 µg of the rat mTOR 
expression vectors (wild type or kinase dead) and 2 µg pRNAT-GFP, allow-
ing the visualization and microdissection of electroporated fibers for further 
gene expression analysis by quantitative real-time PCR. pcDNA3/mTOR 
eukaryotic expression plasmids encoding wild-type or kinase-dead (D2338A) 
rat mTOR were generated previously (Brunn et al., 1997).
ChIP assay
Mouse TA muscles were incubated for 15 min on ice in buffer RBI (100 mM 
KCl, 5 mM MgCl2, 5 mM EDTA, 5 mM Na pyrophosphate, pH 6.8, and JCB • VOLUME 187 • NUMBER 6 • 2009   872
(Vmax) = VADP + V0. The acceptor control ratio = Vmax/V0. Three determi-
nations were made for each muscle sample.
Measurements of muscle contractile properties  
and lengthening contractions
Mice were anesthetised with 60 mg/kg pentobarbital. The knee and foot 
were fixed using clamps and pins. The isometric contractile properties of 
TA muscles were studied in situ as previously described (Mouisel et al., 
2006). The distal tendon of the TA muscle was attached to a lever arm 
of a servomotor system (305B Dual-Mode Lever; Aurora Scientific). All 
data provided by the servomotor system were recorded and analyzed 
on a microcomputer using the PowerLab system (4SP; ADInstruments) 
and  software  (Chart  4;  ADInstruments).  The  sciatic  nerve  (proximally 
crushed)  was  stimulated  by  a  bipolar  silver  electrode  using  a  supra-
maximal (10 V) square wave pulse of 0.1-ms duration. In some instances, 
muscles were directly stimulated (80 V). All isometric contraction mea-
surements were made at an initial muscle length of L0 (length at which 
maximal tension, Pt, was obtained during the twitch). Po was measured 
during isometric contractions in response to electrical stimulation (fre-
quency of 25–150 Hz; train of stimulation of 500 ms). sPo was calcu-
lated by dividing Po by muscle weight. Pt, TTP, and RT50% were also 
measured in response to a single stimulation. The in situ contraction– 
induced injury protocol for the TA muscle used in this study was similar 
to that described previously (Dellorusso et al., 2001). The sciatic nerve 
was stimulated for 300 ms (frequency of 125 Hz). An isometric contrac-
tion of the TA muscle was initiated during the first 100 ms. Then, muscle 
lengthening (3 mm; 45% fiber length [Lf]) at a velocity of 15 mm/s (2 
Lf/s) was imposed during the last 200 ms. Two lengthening contractions 
of the TA muscle were performed, each separated by a 60-s rest period. 
The force deficit after contraction-induced damage was determined by 
calculating  the  difference  between  the  Po  measured  1  min  after  the 
lengthening contractions and the Po determined before lengthening con-
tractions and was expressed as a percentage of Po determined before 
lengthening contractions.
The isometric contractile properties of soleus muscles were studied   
in vitro as previously described (Agbulut et al., 2009). Soleus muscles were 
soaked in an oxygenated Krebs solution (95% O2 and 5% CO2) containing 
58.5 mM NaCl, 24 mM NaHCO3, 5.4 mM KCl, 1.2 mM KH2PO4, 1.8 mM 
CaCl2, 1 mM MgSO4, and 10 mM glucose, pH 7.4, and maintained at a 
temperature of 22°C. One of the muscle tendons was attached to a lever 
arm of a servomotor system (300B Dual-Mode Lever; Aurora Scientific). Af-
ter equilibration (30 min), electrical stimulation was delivered through elec-
trodes running parallel to the muscle. 1-ms pulses were generated by a high 
power stimulator (701B; Aurora Scientific). Po was measured during iso-
metric contractions in response to electrical stimulation (frequency of 50–
125 Hz; train of stimulation of 1,500 ms). sPo was calculated by dividing 
the  force  by  the  estimated  CSA  of  the  muscle.  Assuming  muscles   
have a cylindrical shape and a density of 1.06 mg mm
3, the CSA corre-
sponds to the volume of the muscle divided by Lf. The Lf to L0 ratio of 0.70 
was used to calculate Lf. Fatigue resistance was determined after a 5-min 
rest period. The muscles were stimulated at 50 Hz during 500 ms every 
second for 1 min. The time taken for initial force to fall by 20% (F20%) 
was calculated.
Myosin isoform identification
Muscles were subjected to the analysis of MHC isoforms as described pre-
viously (Talmadge and Roy, 1993). Myosin was extracted from small sec-
tions of muscles in 7 vol of buffer solution (0.3 M NaCl, 0.1 M NaH2PO4, 
0.05 M Na2HPO4, 0.01 M Na4P2O7, 1 mM MgC12-6H2O, 10 mM EDTA, 
and  1.4  mM  2-mercaptoethanol,  pH  6.5).  Myosin  was  separated  in 
acrylamide  gel  solution  containing  30%  glycerol,  8%  acrylamide-bis 
(50:1), 0.2 M Tris, 0.1 M glycine, and 0.4% SDS using a Mini Protean II 
system (Bio-Rad Laboratories). Gels were run at 72 V for 31 h and silver 
stained. The bands were scanned and quantified using a densitometer 
equipped with an integrator (GS-800; Bio-Rad Laboratories).
Statistical analysis
A two-tailed Student’s t test was used for statistical analysis. All data are 
expressed as means ± SEM or SD, and significance was established at the 
P < 0.05 level.
Online supplemental material
Fig. S1 shows the distribution of the different fiber types on soleus muscle 
transverse sections from control and mTOR
 mice. Fig. S2 shows Western 
blot analysis for dystrophy-related proteins in 11-wk-old mTOR
 muscles. 
20 nM rapamycin, or 250 nM Torin1 for 48 h and harvested for gene ex-
pression analysis by quantitative real-time PCR or Western blotting.
Enzyme analysis
Frozen muscle samples were homogenized in a stabilizing medium containing 
50% glycerol, 20 mM phosphate buffer, pH 7.4, 5 mM -mercaptoethanol, 
0.5 mM EDTA, and 0.02% BSA at a dilution of 1:50 based on wet weight. 
All of the enzyme activities were measured at 22°C as described previ-
ously  (Passonneau  and  Lowry,  1993).  Hexokinase  activity  was  deter-
mined in a two-step assay. The glucose-6-phosphate accumulated for 60 min 
in the first step and reacted with NADP and glucose-6-phosphate dehydroge-
nase in a second step. The NADPH generated was detected by fluorescence 
spectroscopy with excitation/emission wavelengths of 350/460 nm. GP, 
PFK, PK, and LDH activities were measured in a one-step spectrophotometer 
assay by directly measuring the rate of appearance or disappearance of 
NADPH/NADH at 340 nm for 10 min. For GP activity measurement, 
glucose-1-phosphate formation was coupled to phosphoglucomutase and 
glucose-6-phosphate  dehydrogenase  reactions.  For  PFK  activity  measure-
ment, fructose-1,6-bisphosphate formation was coupled to aldolase, triose-
phosphate isomerase, and glycerol-3-phosphate dehydrogenase reactions. 
For PK activity measurement, pyruvate formation was coupled to LDH reac-
tion. LDH activity was measured in the direction of lactate formation. Citrate 
synthase activity was determined by using Ellman’s reagent with acetyl-CoA 
and oxaloacetate (Leek et al., 2001). Standards were carried out through 
the entire procedure.
Determination of intramuscular glucose-6-phosphate, lactate,  
and ATP concentrations
Muscles were quickly removed from anesthesized animals, weighted, and 
directly frozen in liquid nitrogen. Muscles were homogenized in 0.65 M 
perchloric acid (1:40 wt/vol) and incubated for 15 min at 4°C. Muscle homog-
enates were centrifuged at 5,000 g for 10 min at 4°C. Resulting acid superna-
tants were neutralized with 2 N KOH in 0.4 M TEA/KCl and used for the 
fluorometric determination of lactate, ATP, and glucose-6-phosphate contents 
by coupled enzyme assays (Passonneau and Lowry, 1993).
Glucose and insulin tolerance tests
For glucose tolerance tests, 12-wk-old male mice were fasted overnight and 
injected intraperitoneally with 3 mg glucose/g body wt. For the insulin toler-
ance test, 4-h-fasted male mice were injected intraperitoneally with insulin 
(0.75 mUI/g body wt; Sigma-Aldrich). Blood glucose levels were determined 
from tail venous blood using an automatic glucose monitor (Roche). Serum 
levels of insulin were determined with murine ELISA kit (Linco Research).
Glucose uptake assays
After cervical dislocation of the mice, the soleus muscle was rapidly isolated 
and tied to stainless steel clips by the tendons. All incubations were per-
formed at 37°C under an atmosphere of 95% O2/5% CO2 in 1 ml Krebs-
Ringer bicarbonate buffer, pH 7.3, supplemented with 1% BSA (fraction V; 
pH 7; Intergen) and 2 mM sodium pyruvate. Glucose transport was mea-
sured as follows: after a preincubation period of 15 min, muscles were incu-
bated for 10 min in the same medium supplemented with 2-[
3H]deoxyglucose 
(0.1 mM and 0.5 µCi/ml). Afterward, muscles were washed for 30 min in 
ice-cold saline buffer and dissolved in 1 N NaOH before scintillation count-
ing for 
3H-labeled radioactivity was performed. Sample aliquots were used 
for protein determination.
Functional properties of mitochondria
Respiratory parameters of the total mitochondrial population were studied 
in situ in fresh saponin-skinned fibers (50 µg/ml saponin for 30 min) and 
determined  with  a  Clark  electrode  (Hansatech  Instruments)  in  an  oxy-
graphic cell at 22°C as described previously (Kuznetsov et al., 2008). Res-
piration rates were expressed as µmol O2/min/g dry weight. Respiration 
solution, pH 7.1, contained 10 mM EGTA-CaEGTA buffer (free Ca
2+ con-
centration 100 nM), 1 mM free Mg
2+, 20 mM taurine, 0.5 mM dithiothrei-
tol, 20 mM imidazole, ionic strength 160 (potassium methane sulfonate), 
5 mM glutamate, 2 mM malate, 3 mM phosphate, and 2 mg/ml BSA. 
Basal oxygen consumption without ADP (V0) was recorded in the presence 
or absence of 20 mM creatine, and increasing amounts of ADP were 
added until maximal respiration was reached. After measurements, fibers 
were carefully removed, dried, and weighed. The ADP-stimulated respira-
tion (VADP) above basal oxygen consumption (V0) was plotted as a function 
of ADP with and without creatine. The apparent Km values for ADP in the 
presence or absence of creatine and VADP were calculated with a nonlinear 
fit  of  the  Michaelis–Menten  equation.  The  maximal  respiration  rate   873 mTOR deficiency leads to severe muscular dystrophy • Risson et al.
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